ES2159811T3 - Uso de antagonistas de estrogenos y agonistas de estrogenos para inhibir condiciones patologicas. - Google Patents

Uso de antagonistas de estrogenos y agonistas de estrogenos para inhibir condiciones patologicas.

Info

Publication number
ES2159811T3
ES2159811T3 ES97301147T ES97301147T ES2159811T3 ES 2159811 T3 ES2159811 T3 ES 2159811T3 ES 97301147 T ES97301147 T ES 97301147T ES 97301147 T ES97301147 T ES 97301147T ES 2159811 T3 ES2159811 T3 ES 2159811T3
Authority
ES
Spain
Prior art keywords
strogen
pathological conditions
agonists
antagonists
inhibit pathological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97301147T
Other languages
English (en)
Inventor
David B Maclean
David D Thompson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2159811T3 publication Critical patent/ES2159811T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

LA PRESENTE INVENCION FACILITA EL USO DE UN COMPUESTO (I) PARA LA ELABORACION DE UN MEDICAMENTO PARA INHIBIR CONDICIONES PATOLOGICAS REFERIDAS A SISTEMAS ORGANICOS QUE RESPONDEN A AGONISTAS DE ESTROGENO:A ES CH{SUB,2} O NR DONDE R ES H O C{SUB,1}-C{SUB,6} ALQUIL, B, D Y E SON CADA UNO CH O N, E Y, Z{SUP,1} Y G SON CIERTOS SUSTITUTIVOS ESTABLECIDOS.
ES97301147T 1996-02-28 1997-02-21 Uso de antagonistas de estrogenos y agonistas de estrogenos para inhibir condiciones patologicas. Expired - Lifetime ES2159811T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1321296P 1996-02-28 1996-02-28

Publications (1)

Publication Number Publication Date
ES2159811T3 true ES2159811T3 (es) 2001-10-16

Family

ID=21758830

Family Applications (2)

Application Number Title Priority Date Filing Date
ES01101953T Expired - Lifetime ES2305003T3 (es) 1996-02-28 1997-02-21 Uso de antagonistas de estrogenos y agonistas de estrogenos en condiciones patologicas de inhibicion.
ES97301147T Expired - Lifetime ES2159811T3 (es) 1996-02-28 1997-02-21 Uso de antagonistas de estrogenos y agonistas de estrogenos para inhibir condiciones patologicas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES01101953T Expired - Lifetime ES2305003T3 (es) 1996-02-28 1997-02-21 Uso de antagonistas de estrogenos y agonistas de estrogenos en condiciones patologicas de inhibicion.

Country Status (16)

Country Link
US (8) US6107331A (es)
EP (2) EP1106179B1 (es)
JP (1) JPH107563A (es)
KR (1) KR970061254A (es)
CN (2) CN1515256A (es)
AT (2) ATE203670T1 (es)
AU (1) AU703473B2 (es)
CA (1) CA2198578C (es)
DE (2) DE69738740D1 (es)
DK (2) DK1106179T3 (es)
ES (2) ES2305003T3 (es)
GR (1) GR3036583T3 (es)
IL (2) IL120266A (es)
MY (1) MY125602A (es)
PT (2) PT792641E (es)
ZA (1) ZA971714B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
EP1027057A4 (en) * 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
ID24568A (id) * 1997-11-06 2000-07-27 American Home Prod Kontrasepsi oral yang mengandung anti-estrogen plus progestin
US6326392B1 (en) 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
EP1004306A3 (en) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen agonists/antagonists
TR200502284T2 (tr) * 1999-07-06 2005-08-22 Endorecherche, Inc. Kilo alımını tedavi ve/veya önleme metotları
US6436977B1 (en) 1999-09-29 2002-08-20 Pfizer Inc. Dosing regimens for lasofoxifene
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5251465A1 (es) * 2000-01-26 2003-02-28 Pfizer Prod Inc Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
AP2002002641A0 (en) 2000-04-07 2002-12-31 Pfizer Prod Inc Estrogen agonist metabolites.
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
ATE346159T1 (de) * 2000-05-08 2006-12-15 Pfizer Prod Inc Enzymatische spaltung von selektiven modulatoren des östrogenrezeptors
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
TWI303990B (en) 2000-10-17 2008-12-11 Pfizer Prod Inc New use of estrogen agonists/antagonists for improving vascular health
AU781168B2 (en) 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
AU2756602A (en) * 2001-04-25 2002-10-31 Pfizer Products Inc. Methods and kits for treating depression or preventing deterioration of cognitive function
GEP20053654B (en) * 2001-05-01 2005-11-10 Pfizer Prod Inc Method For Manufacturing Low Dose Pharmaceutical Composition Having Uniform Drug Distribution
EP1411922A1 (en) * 2001-07-31 2004-04-28 Pfizer Products Inc. Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
WO2003055856A2 (en) * 2001-10-17 2003-07-10 Bristol-Myers Squibb Company BICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE)
CA2496618A1 (en) * 2002-05-23 2003-12-04 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
MXPA05006526A (es) * 2002-12-18 2006-02-17 Besins Int Lab Tratamiento de mastalgia con 4-hidroxi tamoxifen.
EP1658036A2 (en) * 2003-08-26 2006-05-24 Board of Regents of the University of Texas System Estrogen receptor modulators and uses thereof
US20050119276A1 (en) * 2003-09-24 2005-06-02 Wyeth Methods of treating inflammatory bowel disease using NF-kB inhibitors
US7968532B2 (en) * 2003-12-15 2011-06-28 Besins Healthcare Luxembourg Treatment of gynecomastia with 4-hydroxy tamoxifen
US20060079522A1 (en) * 2004-10-08 2006-04-13 Marzabadi Mohammad R Amino substituted aryloxybenzylpiperidine derivatives
US20090082322A1 (en) * 2004-10-09 2009-03-26 The Regents Of The University Of Michigan Gender Differences in Experimental Aortic Aneurysm Formation
US8835413B2 (en) 2004-10-20 2014-09-16 Endorecherche, Inc. Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cGMP phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
US8524663B2 (en) 2006-03-03 2013-09-03 New York University Method for site-specific polyvalent display on polymers
JP5193196B2 (ja) * 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
US20080187894A1 (en) * 2006-12-14 2008-08-07 Cady Roger K Method and System for Interactive Cognitive Testing
EP2195077A1 (en) * 2007-09-21 2010-06-16 Harry Fisch Treatment of migraine headaches using antiestrogens
US8784872B2 (en) * 2007-11-19 2014-07-22 Comgenrx, Inc. Formulation for decreasing tobacco, alcohol, drug or food consumption
WO2009158667A2 (en) * 2008-06-27 2009-12-30 Comgenrx, Inc. Povidone compositions for wound healing
WO2012068284A2 (en) * 2010-11-16 2012-05-24 Baylor University Efficient method for preparing functionalized benzosuberenes
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
WO2018005374A1 (en) 2016-06-27 2018-01-04 Chemocentryx, Inc. Immunomodulator compounds
US20180098963A1 (en) 2016-10-11 2018-04-12 Duke University Lasofoxifene treatment of breast cancer
EP3641793A1 (en) 2017-06-19 2020-04-29 Longeveron LLC Treatment of sexual dysfunction and improvement in sexual quality of life
AU2018306619B2 (en) 2017-07-28 2022-06-02 Chemocentryx, Inc. Immunomodulator compounds
CN111225665B (zh) 2017-08-08 2023-12-08 凯莫森特里克斯股份有限公司 大环免疫调节剂
JP7387616B2 (ja) * 2018-02-22 2023-11-28 ケモセントリックス，インコーポレイティド Ｐｄ－ｌ１アンタゴニストとしてのインダン－アミン
CN117771239A (zh) 2018-04-10 2024-03-29 杜克大学 乳腺癌的拉索昔芬治疗
KR102132554B1 (ko) * 2019-02-25 2020-07-09 가톨릭대학교 산학협력단 랄록시펜을 유효성분으로 함유하는 전신경화증의 예방 또는 치료용 약학적 조성물
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
JP7369437B2 (ja) * 2019-09-27 2023-10-26 国立大学法人三重大学 評価システム、評価方法、学習方法、学習済みモデル、プログラム
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3274213A (en) 1961-09-05 1966-09-20 Upjohn Co Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3396169A (en) 1966-10-26 1968-08-06 Upjohn Co Substituted 2-phenyl-1-(tertiary-aminoalkoxy) phenyl-3, 4-dihydronaphthalenes
US3234090A (en) 1962-09-10 1966-02-08 Ciba Geigy Corp Pharmaceutical compositions comprising saturated basic ethers
US3862232A (en) 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
US3293263A (en) 1963-12-09 1966-12-20 Upjohn Co Diphenylbenzocycloalkenes
US3522319A (en) * 1964-01-23 1970-07-28 Ciba Geigy Corp Phenol substituted tetrahydronaphthalenes useful as estrogenics
IL23284A (en) * 1964-05-01 1969-01-29 Upjohn Co Derivatives of 1,2-diphenyl-3,4-dihydronaphthalenes
US3320271A (en) 1964-06-01 1967-05-16 Upjohn Co 1, 2-diphenyl-3, 4-dihydronaphthalenes and 2, 3-diphenylindenes
US3483293A (en) 1967-12-15 1969-12-09 Upjohn Co Method for controlling birds and rodents
US3567737A (en) * 1968-01-02 1971-03-02 Upjohn Co Derivatives of (2-cycloalkyl-1-phenyl-3,4-dihydronaphthalenes and) 2 - cycloalkyl - 1 - phenyl - 1,2,3,4 - tetrahydro-naphthalenes
US3875242A (en) * 1968-01-02 1975-04-01 Upjohn Co Compounds and process for preparing the same
US4133814A (en) 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
CA1116823A (en) * 1978-05-19 1982-01-26 Gregory C. Bockno Crimped, high-strength rayon yarn and method for its preparation
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
US4358593A (en) 1981-04-03 1982-11-09 Eli Lilly And Company Process for preparing 3-(4-aminoethoxybenzoyl)benzo[b]thiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US4859585A (en) * 1986-04-17 1989-08-22 Trustees Of Tufts College In-vitro methods for identifying compositions which are agonists and antagonists of estrogens
SE452551B (sv) * 1986-05-27 1987-12-07 Camurus Ab Artikel belagd med heparinbaserat material samt forfarande for dess framstellning
DE3733306C1 (de) 1987-10-02 1989-03-02 Judo Wasseraufbereitung Rueckspuelfilter
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
DE4117512A1 (de) 1991-05-25 1992-11-26 Schering Ag 2-phenylbenzo(b)furane und -thiophene, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
GB9121028D0 (en) 1991-10-03 1991-11-13 Pfizer Ltd Therapeutic agents
JP3157882B2 (ja) 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
TW366342B (en) * 1992-07-28 1999-08-11 Lilly Co Eli The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
TW383306B (en) 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol
US5482949A (en) 1993-03-19 1996-01-09 Eli Lilly And Company Sulfonate derivatives of 3-aroylbenzo[b]thiophenes
ES2105525T3 (es) * 1993-06-24 1997-10-16 Lilly Co Eli 2-fenil-3-aroilbenzotiofenos antiestrogenicos como agentes hipoglicemicos.
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5441964A (en) 1993-10-15 1995-08-15 Eli Lilly And Company Methods for inhibiting bone loss using substituted benzothiophene
US5461065A (en) * 1993-10-15 1995-10-24 Eli Lilly And Company Methods for inhibiting endometriosis
US5457116A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods of inhibiting uterine fibrosis
US5391557A (en) * 1993-10-15 1995-02-21 Eli Lilly And Company Methods for the treatment of peri-menopausal syndrome
US5418252A (en) * 1993-10-15 1995-05-23 Eli Lilly And Company Method for inhibiting cartilage degradation
DK0652004T3 (da) * 1993-10-15 2002-09-02 Lilly Co Eli Fremgangsmåder til behandling af resistente neoplasmer
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
US5451590A (en) * 1993-12-21 1995-09-19 Eli Lilly & Co. Methods of inhibiting sexual precocity
US5476862A (en) * 1993-12-21 1995-12-19 Eli Lilly And Company Methods of increasing thrombomodulin expression
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5461064A (en) * 1993-12-21 1995-10-24 Eli Lilly And Company Methods of inhibiting atrophy of the skin and vagina
US5521198A (en) * 1993-12-21 1996-05-28 Eli Lilly And Company Methods of inhibiting autoimmune diseases
US5593987A (en) * 1993-12-21 1997-01-14 Eli Lilly And Company Methods of inhibiting breast disorders
US5708009A (en) * 1993-12-21 1998-01-13 Eli Lilly And Company Methods of inhibiting myeloperoxidase activity
KR950016739A (ko) * 1993-12-21 1995-07-20 피터 지. 스트링거 강박관념 질환 및 소모성 질환을 억제하는 방법
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US5462949A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of inhibiting fertility in women
US5441965A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting thrombin
US5462950A (en) * 1993-12-21 1995-10-31 Eli Lilly And Company Methods of treating menstrual symptoms and compositions therefore
US5389670A (en) 1993-12-21 1995-02-14 Eli Lilly Company Methods of inhibiting the symptoms of premenstrual syndrome/late luteal phase dysphoric disorder
US5552415A (en) * 1993-12-21 1996-09-03 Eli Lilly And Company Method of inhibiting Alzheimer's Disease
US5672610A (en) * 1993-12-21 1997-09-30 Eli Lilly And Company Methods of increasing macrophage function
CZ321394A3 (en) * 1993-12-21 1995-08-16 Lilly Co Eli Pharmaceutical preparation for inhibiting woman hirsutism and alopecia
US5441966A (en) * 1993-12-21 1995-08-15 Eli Lilly And Company Methods of inhibiting Turner's syndrome
US5439931A (en) 1993-12-21 1995-08-08 Eli Lilly And Company Method for increasing libido in post-menopausal women
US5447941A (en) * 1993-12-21 1995-09-05 Eli Lilly And Company Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes
ES2215270T3 (es) * 1993-12-21 2004-10-01 Eli Lilly And Company Inhibicion de productos terminales de glicosilacion avanzada.
US5439923A (en) * 1993-12-21 1995-08-08 Eli Lilly And Company Method of inhibiting seborrhea and acne
US5596004A (en) * 1993-12-21 1997-01-21 Eli Lilly And Company Methods of inhibiting male infertility
US5451589A (en) * 1993-12-21 1995-09-19 Eli Lilly And Company Methods of inhibiting ovarian dysgenesis, delayed puberty, or sexual infantilism
US5446053A (en) * 1993-12-21 1995-08-29 Eli Lilly And Company Methods of inhibiting dysfunctional uterine bleeding
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5470883A (en) * 1994-05-23 1995-11-28 Stromberg; Brent V. Method of treating peripheral vasoconstriction with tamoxifen citrate
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
US5550163A (en) * 1994-08-03 1996-08-27 Allergan, Inc. Method for reducing filtrate waste in a manufacturing process of a pharmaceutical product containing benzalkonium chloride
US5434166A (en) * 1994-08-22 1995-07-18 Eli Lilly And Company Methods of inhibiting demyelinating and desmyelinating diseases
US6399634B1 (en) 1994-09-20 2002-06-04 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
US5510357A (en) 1995-02-28 1996-04-23 Eli Lilly And Company Benzothiophene compounds as anti-estrogenic agents
US5532382A (en) 1995-03-13 1996-07-02 Eli Lilly And Company Benzothiophenes substituted at the 3-carbonyl
US5567828A (en) 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
IL120268A0 (en) 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
WO1997043272A2 (en) 1996-05-14 1997-11-20 Glaxo Group Limited Benzofurans and benzopyrans as chronobiological agents
CA2215647A1 (en) * 1996-10-24 1998-04-24 Eli Lilly And Company Naphthyl compounds, compositions, and methods
AU5550298A (en) * 1997-01-29 1998-08-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor increasing libido in post-menopausal women
EP0977756A1 (en) 1997-04-25 2000-02-09 Pfizer Limited PYRAZOLOPYRIMIDINONES WHICH INHIBIT TYPE 5 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE (cGMP PDE5) FOR THE TREATMENT OF SEXUAL DYSFUNCTION
ZA985543B (en) 1997-06-27 1998-12-28 Smithkline Beecham Corp Novel methods
EP1027057A4 (en) 1997-10-28 2003-01-02 Vivus Inc TREATMENT OF FEMALE SEXUAL DISORDERS
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
TR200200406T2 (tr) 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause

Also Published As

Publication number Publication date
GR3036583T3 (en) 2001-12-31
DK1106179T3 (da) 2008-08-18
CN1515256A (zh) 2004-07-28
EP1106179A2 (en) 2001-06-13
US20030220349A1 (en) 2003-11-27
ES2305003T3 (es) 2008-11-01
JPH107563A (ja) 1998-01-13
AU703473B2 (en) 1999-03-25
CA2198578A1 (en) 1997-08-28
EP1106179A3 (en) 2004-01-07
EP0792641A1 (en) 1997-09-03
MX9701530A (es) 1998-06-30
ATE396728T1 (de) 2008-06-15
US6107331A (en) 2000-08-22
US6355670B1 (en) 2002-03-12
EP1106179B1 (en) 2008-05-28
DE69705874D1 (de) 2001-09-06
ATE203670T1 (de) 2001-08-15
CA2198578C (en) 2002-06-11
KR970061254A (ko) 1997-09-12
US20010018451A1 (en) 2001-08-30
PT1106179E (pt) 2008-07-28
US20040009994A1 (en) 2004-01-15
DE69705874T2 (de) 2001-11-15
US6911456B2 (en) 2005-06-28
US6613796B2 (en) 2003-09-02
DK0792641T3 (da) 2001-10-08
US6274618B1 (en) 2001-08-14
HK1001963A1 (en) 1998-07-24
US20020091121A1 (en) 2002-07-11
IL164967A0 (en) 2005-12-18
CN1122513C (zh) 2003-10-01
CN1167617A (zh) 1997-12-17
PT792641E (pt) 2001-11-30
IL120266A (en) 2005-05-17
IL120266A0 (en) 1997-06-10
US20050148625A1 (en) 2005-07-07
MY125602A (en) 2006-08-30
EP0792641B1 (en) 2001-08-01
DE69738740D1 (de) 2008-07-10
US6403611B2 (en) 2002-06-11
ZA971714B (en) 1997-08-27
AU1497997A (en) 1997-09-04

Similar Documents

Publication Publication Date Title
ES2159811T3 (es) Uso de antagonistas de estrogenos y agonistas de estrogenos para inhibir condiciones patologicas.
DE69735108D1 (de) A-1-adenosin rezeptor antagoniste
KR970700181A (ko) 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체(Synthetic intermediates for preparing retroviral protease inhibiting compounds)
DK0842661T3 (da) Anvendelse af estrogenagonister og -antagonister til fremstilling af et lægemiddel til behandling af atherosclerose, uafhængigt af lipidsænkning
IT1283588B1 (it) Miscela sinergica di agenti stabilizzanti
BR0009314B1 (pt) compostos, composição fungicida, método de combate a fungos e uso de um composto.
EA199800141A1 (ru) Гетероциклические соединения
FI931067A0 (fi) Antitumoera foereningar
BG92804A (bg) 4-бензоилизоксазолови производни
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
DK0918776T3 (da) Totalsyntese af antitumor acylfulvener
UA27220C2 (uk) Спосіб одержання похідних 1-фенілімідазолін-2,5-діону
ES2155655T3 (es) Compuestos de benzotiofeno, usos y formulaciones de los mismos.
FI901277A0 (fi) 2,5,6,7-tetranor-4,8-inter-m-fenylen pg1z-derivativ.
ATE284379T1 (de) Aminderivate
ATE105565T1 (de) Pradimicinderivate.
BR9912885A (pt) Derivado de 3-azabiciclo-[3.2.0]- heptano n-substituìdo
BR9305092A (pt) Processo para a preparação de derivados de 5-pirazolmercáptan, composto ditiocarbazato de etilideno, processo para a preparação de derivados do mesmo
ES2145899T3 (es) Derivados de feniltio-oxazolina.
DK1140932T3 (da) Derivater af benzo-1,8-naphtyridin

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 792641

Country of ref document: ES